UNSPSC 51282105: Latamoxef or moxalactam

This classification denotes a beta-lactam antibiotic with the molecular formula C20H20N6O9S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VUF6C936Z3, chemically known as 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (6r-(6alpha,7alpha,7(s*)))- but generally known as latamoxef, which bears US NIH Compound Identifier 47499.

UNSPSC 51282105 Latamoxef or moxalactam is a Commodity code that maps poorly to actual state and local procurement activity; the code does not align with the recent opportunities posted under it. The recent solicitations show state and local governments purchasing naloxone, first aid and rescue supplies, generic pharmaceuticals, and over-the-counter products through various issuing bodies, but latamoxef and moxalactam—both third-generation beta-lactam antibiotics—do not appear in any of the named opportunities. The mismatch suggests either a classification error in the tagging system or that this code sees minimal relevant recent activity in state and local procurement.

Across the four recent opportunities, issuing bodies include a Florida county health authority (Seminole County), a state health and human services commission (Texas HHS), a municipal fire department procurement function (City of Tampa), and a multi-state cooperative purchasing alliance (MMCAP, administered by Minnesota). The opportunities span naloxone and drug deactivation systems (IFB, due July 26, 2023, estimated scope 1,900 units annually), direct-to-manufacturer prescription programs (RFI, April 3, 2026), Tampa Fire Department rescue supplies including respiratory equipment and cardiac monitoring devices (IFB, $700,000 estimated contract value, due March 13, 2026, with a 5 percent bid discount for certified Small Local Business Enterprises), and generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (RFP, proposals due March 26, 2026, effective July 1, 2026). Geographic activity includes Florida, Texas, Minnesota, and Oregon through the cooperative purchasing vehicle. The code shows recent activity concentrated in multi-state and regional procurement mechanisms rather than standalone state or local department solicitations, but the work being bought does not match the code's nominal pharmaceutical scope.